Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea

Acta Haematol. 2003;109(3):161-2. doi: 10.1159/000069288.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bone Marrow / pathology
  • Busulfan / administration & dosage
  • Busulfan / adverse effects*
  • Humans
  • Hydroxyurea / administration & dosage
  • Hydroxyurea / adverse effects*
  • Leukemia, Megakaryoblastic, Acute / etiology*
  • Leukemia, Megakaryoblastic, Acute / pathology
  • Male
  • Megakaryocytes / pathology
  • Middle Aged
  • Pipobroman / administration & dosage
  • Pipobroman / adverse effects*
  • Thrombocythemia, Essential / complications*
  • Thrombocythemia, Essential / drug therapy*
  • Time Factors

Substances

  • Pipobroman
  • Busulfan
  • Hydroxyurea